kidney
Advertisement
A report based on chart data and specialist surveys reveals gaps in treatment for FSGS but optimism about the drug pipeline.
The FDA has granted Orphan Drug Designation to veverimer for anti–glomerular basement membrane (anti-GBM) disease.
Richard Furie, MD, discussed the REGENCY trial of obinutuzumab in systemic lupus erythematosus and lupus nephritis.
Gene sequencing of a patient with gouty sacroiliitis and gouty nephropathy highlighted genetic factors leading to gout.
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis.
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
Hemodialysis patients reporting shorter sleep or problems sleeping had a higher mortality risk in an observational study.
Finerenone had kidney and cardiovascular benefits for patients with CKD even after an acute eGFR change occurred.
Higher cardiovascular mortality risk was associated with higher CKM syndrome stage, research showed.
The Annual Global Summit on Kidney Disease Innovations included sessions on rare diseases, human organ alternatives, and more
A dual SGLT inhibitor may have ischemic benefits for patients with CKD, T2D, and cardiovascular risks, a study found.
An analysis of CKD trials supported 3-year total slope as the primary slope-based outcome in randomized trials.
Cyclophosphamide-rituximab therapy and minimal use of glucocorticoids in ANCA-associated vasculitis may reduce morbidity.
A study of real-world data found that tolvaptan reduced long-term kidney function decline in ADPKD.
In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.